A phase 3 trial of Roche’s giredestrant in first-line breast cancer patients has missed its primary endpoint, tarnishing the record of a drug that hit the mark in adjuvant and second-line settings.
The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...
Hosted on MSN
Survival rates for cancer are the highest they’ve ever been — but these 3 will cause the most deaths in 2026
Cancer statistics have reached new heights — in good and not-so-good ways. The American Cancer Society (ACS) released its annual report on cancer trends this week, showing for the first time that more ...
Researchers from the Johns Hopkins Kimmel Cancer Center and The Johns Hopkins University have created a novel database structure that allows investigators anywhere to more easily study multiple types ...
The evolving story of GLP-1 receptor agonists in oncology has yet another new chapter.Several studies presented at San Antonio Breast Cancer Symposium suggested the medications may help extend ...
Researchers from the Johns Hopkins Kimmel Cancer Center and The Johns Hopkins University have created a novel database structure that allows investigators anywhere to more easily ...
The study analyzed data from more than 1.8 million people for 16 years ...
Earlier analyses demonstrated strong local tumor control, with nearly nine in 10 patients remaining free of recurrence at three years. The completion of five-year follow-up marks an important ...
The alternative medicine industry is expanding rapidly, fueled in large part by the surge of health-related content on social ...
The University of Hawaii confirmed that a ransomware gang stole the data of nearly 1.2 million individuals in August 2025 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results